Myriad Genetics (MYGN) investor relations material

Leadership insights and management philosophy

• CEO and board members recently purchased shares, reflecting strong conviction in the company’s direction.

• CEO’s first year emphasized customer trust, product quality, and scientific leadership.

• Leadership team expanded with experienced hires from industry leaders to drive execution excellence.

• CFO highlighted a shift to a culture of disciplined execution and process improvement.

Strategic priorities and growth drivers

• Focused on consistent delivery of financial targets and timely product launches.

• Updated strategy centers on the Cancer Care Continuum, leveraging hereditary cancer strengths and expanding into high-growth areas like MRD.

• Reorganized sales structure, splitting women’s health into dedicated channels for unaffected and prenatal segments.

• Efficiency initiatives freed up $35 million for reinvestment and improved sales effectiveness.

Financial outlook and guidance

• Guidance for $870 million at midpoint assumes mid-single-digit sequential growth after Q1.

• H2 historically contributes a higher revenue proportion; new product launches and channel strategies expected to drive growth.

• GeneSight expected to grow at mid-single-digit rates, supported by payer additions and biomarker legislation.

• Prenatal segment anticipated to return to growth in Q2, with FirstGene launch in Q3.